Bluejay Therapeutics
Jeff Zablocki has a diverse work experience in the pharmaceutical industry. Jeff is currently the VP Head of Chemistry at BlueJay Therapeutics since November 2021. Prior to that, they held the position of Head of Medicinal Chemistry at Pharmacyclics, an AbbVie Company from August 2018 to February 2022. Jeff also served as a Senior Director and Head of Cardiovascular Chemistry at Gilead Sciences starting from June 2009. Jeff's earlier roles include being the Head of Chemistry at CV Therapeutics from May 1998 to June 2009, and a Senior Scientist at Amgen from April 1995 to May 1998. Jeff began their career as a Senior Scientist at Pharmacia and Searle/Monsanto in 1989. Overall, Jeff has had extensive experience in medicinal chemistry, managing teams of chemists, and supporting clinical trials in various pharmaceutical companies.
Jeff Zablocki earned their Bachelor's degree in Organic Chemistry from the University of Illinois Urbana-Champaign. Jeff then went on to further their education and obtained a PhD in the same field from the same institution. Following their PhD, Jeff pursued a Post-Doc at UC Irvine, focusing on Organic Chemistry.
This person is not in any teams
Bluejay Therapeutics
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate offunctional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.